Download Document

The cooperation between doxorubicin and ALTSPC
make a better effect in killing cancer cells
Yan-Li Qin, Xiao-Huang and Ji-Yao Chen
a 5 abs
dox 5 abs
a dox 5 5 abs
dox 10 abs
a dox 5 10 abs
0.30
0.28
0.26
Altspc 5
dox 10
a:dox 5:10
250
Dox (positive)
350
200
0.22
250
0.20
0.18
ALTSPC (negative)
a 5 excit
dox 10 feng1 excit
dox 10 feng2 excit
a dox 5 10 feng1 excit
a dox 5 10 feng2 excit
a dox 5 10 feng3 excit
300
0.24
150
200
0.16
0.14
B
B
B
samples
Abstract: Aluminium tetrasulfonated phthalocyanine(AlTSPc)
is a nontoxic PDT drug, which is FDA approved for clinical
trials against tumors. But the time of it entering cancer cells is
long, and its fluorescence is not strong enough to detect.
Doxorubicin is another medicine that cure cancer cells, it
enters cells must faster than ALTSPC and it has much strong
fluorescence. We let the two samples work together. As a
result, their cooperation get a better effect in killing cancer
cells.
100
0.12
0.10
150
100
0.08
50
0.06
electrop
horesis
50
0.04
0.02
0
0
0.00
300
400
500
600
A
700
400
450
500
550
600
650
700
750
800
850
A
Abs spectrum
Fl spectrum
300
320
340
360
380
400
420
440
460
480
500
520
A
Ex spectrum
They connect with each other
because of electric force
The spectrums above tell that there are interaction
between the two samples
Cell livability
MTT
C: control A: ALTSPC
D: doxorubicin L: light
Samples
Fl of dox in
RBL cells
DIC pictures of
RBL cells
Fl of ALTSPC in
RBL cells
Given more time ,the effect will be more
clear
Conclusions
ALTSPC is negative charged, doxorubicin is positive charged. We mix their solution together. The electricphoresis tells
us that they connect with each other because of their electric force. From the spectrums we know that there are FRET
effect between them. By the MTT assay, we know more cancer cells are killed just because of their cooperation. So we
hope that they will cooperate together to kill more cancer cells with a faster speed.
References:
(1) Ying-jun chen, xiu-ping Yan, SMALL.2009,5,NO. 17, 2012-2018.
(2) Sharman, W. M.; Allen, C. M.; van Lier, J. E. Drug Discovery Today 1999, 4,507–517